Keymed and Lepu Biopharma Jointly Announces Global Exclusive Licence Agreement with Astrazeneca for Cmg901
ownership).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.04 HKD | +7.23% | +16.94% | +19.71% |
Apr. 12 | Keymed Biosciences Advances Solid Tumors Drug With First Patient Study | MT |
Mar. 27 | Lepu Biopharma Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
11,988 GBX | -0.32% | +9.52% | 231B | ||
34.9 HKD | -0.14% | +27.14% | 1.23B | ||
5.04 HKD | +7.23% | +16.94% | 1.07B | ||
1st Jan change | Capi. | |
---|---|---|
+19.71% | 1.07B | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |